Jounce Therapeutics has completed a pre-planned data review of the INNATE Phase 2 trial of JTX

Key Highlights :

1. Patients in the INNATE trial are experiencing deep and durable responses.

2. A data review was conducted to assess the potential to achieve proof-of-concept in the ovarian cancer combination cohort of the INNATE trial.

3. The ovarian cancer combination cohort would meet Jounce internal criteria for POC, based on a statistically meaningful improvement over the benchmark of pembrolizumab alone in the analogous setting.

4. Jounce is seeking to partner JTX-8064.

5. Jounce continues to believe a company with additional resources and a longer value creation timeline could potentially advance this program for the benefit of cancer patients.

Jounce Therapeutics, Inc. announced that patients from the INNATE Phase 2 trial in the ovarian cancer combination cohort with platinum resistant ovarian cancer are experiencing deep and durable responses based on a pre-planned informal data review.

Continue Reading at Source : globenewswire